



Market Announcement

8 October 2019

Clinuvel Pharmaceuticals Limited (ASX: CUV) – Trading Halt

Description

The securities of Clinuvel Pharmaceuticals Limited ('CUV') will be placed in trading halt at the request of CUV, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 11 October 2019 or when the announcement is released to the market.

Issued by

Cheng Tang

Senior Adviser, Listings Compliance (Melbourne)



Ms Cheng Tang
Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
Level 4, Rialto North Tower
525 Collins Street
Melbourne VIC 3000

By Email: cheng.tang@asx.com.au

08 October 2019

CLINUVEL PHARMACEUTICALS LTD (ASX:CUV) - REQUEST FOR TRADING HALT

Dear Ms Tang,

Pursuant to Listing Rule 17.1, Clinuvel Pharmaceuticals Ltd ACN 089 644 119 (CUV) requests a trading halt with respect to its ordinary shares listed on the Australian Securities Exchange (ASX).

The trading halt is requested by CUV pending a material announcement to the market regarding a decision by the US Food and Drug Administration (FDA) on the review of CUV's New Drug Application (NDA) for marketing approval of SCENESSE® (afamelanotide 16mg) to treat erythropoietic protoporphyria (EPP). The FDA has advised a decision date of 8th October 2019 (US time) to the review of the NDA. The trading halt is necessary as otherwise trading in CUV's securities might occur whilst the market as a whole is not reasonably informed.

CUV requests the trading halt to last until the earlier of CUV releasing an announcement in relation to the outcome to the review process or until the commencement of trade on Friday 11th October 2019.

CUV is not aware of any reason why the trading halt should not be granted by the ASX, nor is it aware of any other information that is necessary to inform the market about the trading halt.

Yours respectfully,

A handwritten signature in blue ink, appearing to read "D. Keamy", with a long horizontal stroke extending to the right.

Mr Darren Keamy
Company Secretary
Clinuvel Pharmaceuticals Ltd